| Abstrakt: |
The article discusses the introduction of Rezūm water vapor thermal therapy for benign prostatic hyperplasia in Japan, with the first cases being performed in October 2022. The study focuses on a cohort of elderly patients and those at high risk for anesthesia, showing promising results in terms of subjective symptom improvement and catheter-free rates. While there are some limitations, such as missing data and lack of improvement in maximum flow rate, Rezūm therapy is presented as a practical minimally invasive surgical treatment option in Japan, especially for patients unsuitable for other surgeries like holmium laser enucleation of the prostate. [Extracted from the article] |
Plný text